Form 4: Caribou Biosciences CLO Reports Equity Grants, Tax Sale

Caribou Biosciences' Chief Legal Officer, Barbara G. McClung, reported the acquisition of restricted stock units and stock options, alongside a tax-related sale of common stock.

Summary

• Barbara G. McClung, Chief Legal Officer of Caribou Biosciences, Inc. (CRBU), reported several equity transactions.
• On February 20, 2026, McClung acquired 45,000 restricted stock units (RSUs) and 202,500 options to purchase common stock.
• The RSUs will vest in four equal annual installments starting February 20, 2027, contingent on continued service to the Issuer.
• The stock options have an exercise price of $1.80 and will vest monthly over four years, fully vesting by February 20, 2030, also subject to continued service.
• On February 24, 2026, McClung disposed of 6,938 shares of common stock at a price of $1.96 per share.
• This disposition was a "sell-to-cover" transaction, executed under a Rule 10b5-1 trading plan, solely to satisfy tax withholding obligations related to previously vested RSUs, and was not a discretionary trade.
• Following these transactions, McClung beneficially owns 481,564 shares of common stock and 202,500 options to purchase common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting ongoing executive compensation and retention, with the disposition being a non-discretionary tax event rather than a voluntary sale.

Positives

• Chief Legal Officer Barbara G. McClung received a grant of 45,000 restricted stock units (RSUs) and 202,500 stock options, aligning her interests with shareholders.
• The equity grants demonstrate continued commitment to key management personnel, incentivizing long-term service.

Negatives

• A disposition of 6,938 shares of common stock occurred, though it was a non-discretionary "sell-to-cover" for tax obligations rather than a voluntary sale.

Risks

• The vesting of both RSUs and stock options is contingent upon the reporting person continuing to provide service to the Issuer through the applicable vesting dates.

Future Outlook

The reporting person's equity compensation is structured with future vesting schedules, indicating a long-term incentive for continued service to Caribou Biosciences, Inc. The RSUs will vest annually starting February 20, 2027, and stock options will vest monthly, fully by February 20, 2030.

Management Comments

• The disposition of 6,938 shares was a "sell-to-cover" transaction solely to satisfy tax withholding obligations in connection with the vesting of previously granted RSUs, and it does not represent a discretionary trade.
• The "sell-to-cover" transaction was made pursuant to a Rule 10b5-1 trading plan adopted prior to the 2023 amendments, which provides for the automatic sale of shares necessary to satisfy tax withholding obligations.

Industry Context

StockSavvy.ai notes that equity compensation, including restricted stock units and stock options, is a standard practice across the biotechnology and pharmaceutical industries to attract, retain, and incentivize key executives. The use of Rule 10b5-1 plans for tax-related sales is also a common and compliant mechanism for insiders to manage their equity holdings.

Comparison to Industry Standards

• The structure of equity grants with multi-year vesting schedules is consistent with industry standards for executive compensation, aiming to align long-term executive performance with shareholder value.
• The use of a "sell-to-cover" transaction under a Rule 10b5-1 plan for tax obligations is a widely accepted and transparent method for insiders to manage tax liabilities arising from equity vesting, seen across publicly traded companies.

Stakeholder Impact

• Shareholders: The grants align management's interests with shareholders through equity ownership, potentially fostering long-term value creation. The tax-related sale is a routine event with minimal direct impact.
• Employees: The compensation structure for a key executive may set a precedent or reflect the company's overall approach to incentivizing its workforce.

Next Steps

• Vesting of 45,000 Restricted Stock Units (RSUs) in four equal annual installments beginning February 20, 2027.
• Monthly vesting of 202,500 stock options, leading to full vesting by February 20, 2030.
• Settlement of RSUs in stock within 30 days after each vesting date.

Key Dates

Keywords

CRBU, Caribou Biosciences, Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Stock Options, Rule 10b5-1, Sell-to-Cover